David Nathan

David Nathan, MD

President Emeritus, Dana-Farber Cancer Institute

Robert A. Stranahan Distinguished Professor of Pediatrics, Harvard Medical School

    Contact: 617-632-2155
  • Fax: 617-632-2161

Medical Services


  • Thalassemia
  • Sickle Cell Disease
  • Aplastic Anemia


  • Hematology / Oncology
To schedule an appointment: Call 617-632-2155

Experience and Education


Medical School

Harvard Medical School, 1955

Boston, MA


Brigham and Women's Hospital, 1955-1956

Boston, MA


Brigham and Women's Hospital, 1958-1959

Boston, MA


National Cancer Institute, 1956-1958

Bethesda, MD



Publications powered by Harvard Catalyst Profiles
  1. Nathan DG. Training. Pediatr Blood Cancer. 2018 Feb; 65(2).
  2. Nathan DG. Cholesterol: the debate should be terminated. FASEB J. 2017 Jul; 31(7):2722-2728.
  3. Nathan DG, Nathan DM. Eulogy for the clinical research center. J Clin Invest. 2016 Jul 01; 126(7):2388-91.
  4. Nathan DG. Thalassemia: a look to the future. Ann N Y Acad Sci. 2016 Mar; 1368(1):11-5.
  5. Nathan DG. Amino acid uptake in erythropoiesis. Sci Signal. 2015 Apr 14; 8(372):fs9.
  6. Nathan D, Neill US. A conversation with David Nathan. J Clin Invest. 2014 Dec; 124(12):5090-1.
  7. Archer NM, Shmukler BE, Andolfo I, Vandorpe DH, Gnanasambandam R, Higgins JM, Rivera A, Fleming MD, Sachs F, Gottlieb PA, Iolascon A, Brugnara C, Alper SL, Nathan DG. Hereditary xerocytosis revisited. Am J Hematol. 2014 Dec; 89(12):1142-6.
  8. Benz EJ, Nathan DG. A tribute to Emil Frei III. J Clin Invest. 2013 Aug 1; 123(8):3188-9.
  9. Nienhuis AW, Nathan DG. Pathophysiology and Clinical Manifestations of the ß-Thalassemias. Cold Spring Harb Perspect Med. 2012 Dec 01; 2(12):a011726.
  10. Sankaran VG, Ghazvinian R, Do R, Thiru P, Vergilio JA, Beggs AH, Sieff CA, Orkin SH, Nathan DG, Lander ES, Gazda HT. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest. 2012 Jul; 122(7):2439-43.
  11. Show all
  12. Nathan DG, Field J, Lin G, Neuberg D, Majerus E, Onyekwere O, Keefer J, Okam M, Ross A, Linden J. Sickle cell disease (SCD), iNKT cells, and regadenoson infusion. Trans Am Clin Climatol Assoc. 2012; 123:312-7; discussion 317-8.
  13. Musallam KM, Sankaran VG, Cappellini MD, Duca L, Nathan DG, Taher AT. Fetal hemoglobin levels and morbidity in untransfused patients with ß-thalassemia intermedia. Blood. 2012 Jan 12; 119(2):364-7.
  14. Nathan DG. Guilt by association. Blood. 2011 Oct 06; 118(14):3758-9.
  15. Sankaran VG, Nathan DG. Reversing the hemoglobin switch. N Engl J Med. 2010 Dec 02; 363(23):2258-60.
  16. Sankaran VG, Nathan DG. Thalassemia: an overview of 50 years of clinical research. Hematol Oncol Clin North Am. 2010 Dec; 24(6):1005-20.
  17. Nathan DG. A life-long quest to understand and treat genetic blood disorders. Cell. 2010 Oct 01; 143(1):17-20.
  18. Bunn HF, Nathan DG, Dover GJ, Hebbel RP, Platt OS, Rosse WF, Ware RE. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood. 2010 Aug 05; 116(5):687-92.
  19. Nathan DG, Orkin SH. Musings on genome medicine: Hepatitis C. Genome Med. 2010 Jan 27; 2(1):4.
  20. Verduzco LA, Nathan DG. Sickle cell disease and stroke. Blood. 2009 Dec 10; 114(25):5117-25.
  21. Nathan DG, Orkin SH. Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases. Genome Med. 2009 Dec 09; 1(12):114.
  22. Nathan DG, Orkin SH. Musings on genome medicine: Crohn's disease. Genome Med. 2009 Nov 05; 1(11):103.
  23. Nathan DG, Orkin SH. Musings on genome medicine: the slow but inexorable process of medical care reform in the United States. Genome Med. 2009 Oct 12; 1(10):94.
  24. Nathan DG. Call for a slower approach to health care reform. J Clin Invest. 2009 Oct; 119(10):2847-8.
  25. Nathan DG, Orkin SH. Musings on genome medicine: the Obama effect redux. Genome Med. 2009 Sep 11; 1(9):86.
  26. Nathan DG, Orkin SH. Musings on genome medicine: cholesterol and coronary artery disease. Genome Med. 2009 Jun 08; 1(6):60.
  27. Nathan DG, Orkin SH. Musings on genome medicine: cancer genetics and the promise of effective treatment. Genome Med. 2009 May 06; 1(5):49.
  28. Nathan DG, Orkin SH. Musings on genome medicine: gene therapy. Genome Med. 2009 Apr 03; 1(4):38.
  29. Nathan DG, Orkin SH. Musings on genome medicine: the Obama effect. Genome Med. 2009 Mar 09; 1(3):30.
  30. Nathan DG, Orkin SH. Musings on genome medicine: abuse of genetic tests. Genome Med. 2009 Feb 16; 1(2):18.
  31. Nathan DG, Orkin SH. Musings on genome medicine: genome wide association studies. Genome Med. 2009 Jan 20; 1(1):3.
  32. Nathan DG, Gimbrone MA. Judah Folkman, MD, 1933-2008. Pharos Alpha Omega Alpha Honor Med Soc. 2009; 4-8.
  33. Benz EJ, Nathan DG, Amaravadi RK, Danial NN. Targeting the cell death-survival equation. Clin Cancer Res. 2007 Dec 15; 13(24):7250-3.
  34. Nathan DG. Stanley J. Korsmeyer. Proc Am Philos Soc. 2007 Jun; 151(2):243-6.
  35. Nathan DG. Acceptance of the 2006 Kober medal. J Clin Invest. 2007 Apr; 117(4):1107-13.
  36. Nathan DG. The cancer treatment revolution. Trans Am Clin Climatol Assoc. 2007; 118:317-23.
  37. Gazda HT, Grabowska A, Merida-Long LB, Latawiec E, Schneider HE, Lipton JM, Vlachos A, Atsidaftos E, Ball SE, Orfali KA, Niewiadomska E, Da Costa L, Tchernia G, Niemeyer C, Meerpohl JJ, Stahl J, Schratt G, Glader B, Backer K, Wong C, Nathan DG, Beggs AH, Sieff CA. Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am J Hum Genet. 2006 Dec; 79(6):1110-8.
  38. Nathan DG, Schechter AN. NIH support for basic and clinical research: biomedical researcher angst in 2006. JAMA. 2006 Jun 14; 295(22):2656-8.
  39. Nathan DG. The several Cs of translational clinical research. J Clin Invest. 2005 Apr; 115(4):795-7.
  40. Cunningham MJ, Nathan DG. New developments in iron chelators. Curr Opin Hematol. 2005 Mar; 12(2):129-34.
  41. Nathan DG. Thalassemia: the continued challenge. Ann N Y Acad Sci. 2005; 1054:1-10.
  42. Gazda HT, Zhong R, Long L, Niewiadomska E, Lipton JM, Ploszynska A, Zaucha JM, Vlachos A, Atsidaftos E, Viskochil DH, Niemeyer CM, Meerpohl JJ, Rokicka-Milewska R, Pospisilova D, Wiktor-Jedrzejczak W, Nathan DG, Beggs AH, Sieff CA. RNA and protein evidence for haplo-insufficiency in Diamond-Blackfan anaemia patients with RPS19 mutations. Br J Haematol. 2004 Oct; 127(1):105-13.
  43. Nathan DG. Determination can win the battle. Lancet. 2004 Jul 17-23; 364(9430):301.
  44. Nathan DG. Acceptance of the 2003 John Howland Award: a journey in clinical research. Pediatr Res. 2004 Aug; 56(2):169-76.
  45. Nathan DG, Wilson JD. Clinical research and the NIH--a report card. N Engl J Med. 2003 Nov 06; 349(19):1860-5.
  46. Thadhani R, Wolf M, Hsu-Blatman K, Sandler L, Nathan D, Ecker JL. First-trimester sex hormone binding globulin and subsequent gestational diabetes mellitus. Am J Obstet Gynecol. 2003 Jul; 189(1):171-6.
  47. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Séchaud R, Krebs-Brown AJ, Anderson JR, Alberti D, Sizer KC, Nathan DG. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003 May 10; 361(9369):1597-602.
  48. Brittenham GM, Nathan DG, Olivieri NF, Pippard MJ, Weatherall DJ. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet. 2003 Jan 11; 361(9352):183; author reply 183-4.
  49. Nathan DG. Clinical research: a tale of two studies. Trans Am Clin Climatol Assoc. 2003; 114:219-30; discussion 230-2.
  50. Nathan DG, Weatherall DJ. Academic freedom in clinical research. N Engl J Med. 2002 Oct 24; 347(17):1368-71.
  51. Shimamura A, Montes de Oca R, Svenson JL, Haining N, Moreau LA, Nathan DG, D'Andrea AD. A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood. 2002 Dec 15; 100(13):4649-54.
  52. Nathan DG. Careers in translational clinical research-historical perspectives, future challenges. JAMA. 2002 May 08; 287(18):2424-7.
  53. Nathan DG. Educational-debt relief for clinical investigators--a vote of confidence. N Engl J Med. 2002 Jan 31; 346(5):372-4.
  54. Nathan D, Benz EJ. Comprehensive cancer centres and the war on cancer. Nat Rev Cancer. 2001 Dec; 1(3):240-5.
  55. Lopes de Faria JM, Katsumi O, Cagliero E, Nathan D, Hirose T. Neurovisual abnormalities preceding the retinopathy in patients with long-term type 1 diabetes mellitus. Graefes Arch Clin Exp Ophthalmol. 2001 Sep; 239(9):643-8.
  56. Gazda H, Lipton JM, Willig TN, Ball S, Niemeyer CM, Tchernia G, Mohandas N, Daly MJ, Ploszynska A, Orfali KA, Vlachos A, Glader BE, Rokicka-Milewska R, Ohara A, Baker D, Pospisilova D, Webber A, Viskochil DH, Nathan DG, Beggs AH, Sieff CA. Evidence for linkage of familial Diamond-Blackfan anemia to chromosome 8p23.3-p22 and for non-19q non-8p disease. Blood. 2001 Apr 01; 97(7):2145-50.
  57. Nathan DG, Varmus HE. The National Institutes of Health and clinical research: a progress report. Nat Med. 2000 Nov; 6(11):1201-4.
  58. Sieff CA, Nisbet-Brown E, Nathan DG. Congenital bone marrow failure syndromes. Br J Haematol. 2000 Oct; 111(1):30-42.
  59. Rebel VI, Tanaka M, Lee JS, Hartnett S, Pulsipher M, Nathan DG, Mulligan RC, Sieff CA. One-day ex vivo culture allows effective gene transfer into human nonobese diabetic/severe combined immune-deficient repopulating cells using high-titer vesicular stomatitis virus G protein pseudotyped retrovirus. Blood. 1999 Apr 01; 93(7):2217-24.
  60. Nathan DG, Weatherall DJ. Academia and industry: lessons from the unfortunate events in Toronto. Lancet. 1999 Mar 06; 353(9155):771-2.
  61. Nathan DG, Weatherall DJ. Iron chelation with oral deferiprone in patients with thalassemia. N Engl J Med. 1998 Dec 03; 339(23):1711-2; author reply 1713-4.
  62. Nathan DG. Clinical research: perceptions, reality, and proposed solutions. National Institutes of Health Director's Panel on Clinical Research. JAMA. 1998 Oct 28; 280(16):1427-31.
  63. Nathan DG. Pioneers and modern ideas. Prospective on thalassemia. Pediatrics. 1998 Jul; 102(1 Pt 3):281-3; discussion 288-9.
  64. Jubinsky PT, Krijanovski OI, Nathan DG, Tavernier J, Sieff CA. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood. 1997 Sep 01; 90(5):1867-73.
  65. Jubinsky PT, Shikama Y, Laurie A, Nathan DG, Carroll M, Sieff CA. The beta c component of the granulocyte-macrophage colony-stimulating factor (GM-CSF)/interleukin 3 (IL-3)/IL-5 receptor interacts with a hybrid GM-CSF/erythropoietin receptor to influence proliferation and beta-globin mRNA expression. Mol Med. 1996 Nov; 2(6):766-73.
  66. Taylor DS, Laubach JP, Nathan DG, Mathey-Prevot B. Cooperation between core binding factor and adjacent promoter elements contributes to the tissue-specific expression of interleukin-3. J Biol Chem. 1996 Jun 14; 271(24):14020-7.
  67. Janov AJ, Leong T, Nathan DG, Guinan EC. Diamond-Blackfan anemia. Natural history and sequelae of treatment. Medicine (Baltimore). 1996 Mar; 75(2):77-8.
  68. Parsons SK, Fleming MD, Nathan DG, Andrews NC. Iron Deficiency Anemia Associated with an Error of Iron Metabolism in Two Siblings: A Thirty Year Follow Up. Hematology. 1996; 1(1):65-73.
  69. Nathan DG. An orally active iron chelator. N Engl J Med. 1995 Apr 06; 332(14):953-4.
  70. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994 Sep 01; 331(9):574-8.
  71. Davies K, TePas EC, Nathan DG, Mathey-Prevot B. Interleukin-3 expression by activated T cells involves an inducible, T-cell-specific factor and an octamer binding protein. Blood. 1993 Feb 15; 81(4):928-34.
  72. Lovejoy FH, Ledley FD, Nathan DG. Academic careers: choice and activity of graduates of a pediatric residency program 1974-1986. Trans Am Clin Climatol Assoc. 1993; 104:180-95; discussion 195-7.
  73. McDonagh KT, Dover GJ, Donahue RE, Nathan DG, Agricola B, Byrne E, Nienhuis AW. Hydroxyurea-induced HbF production in anemic primates: augmentation by erythropoietin, hematopoietic growth factors, and sodium butyrate. Exp Hematol. 1992 Nov; 20(10):1156-64.
  74. Goldmann DA, Andrews SM, Pasternack S, Nathan DG, Lovejoy FH. A service chief model for general pediatric inpatient care and residency training. Pediatrics. 1992 Apr; 89(4 Pt 1):601-7.
  75. Lovejoy FH, Nathan DG. Careers chosen by graduates of a major pediatrics residency program, 1974-1986. Acad Med. 1992 Apr; 67(4):272-4.
  76. Ezekowitz RA, Sieff CA, Dinauer MC, Nathan DG, Orkin SH, Newburger PE. Restoration of phagocyte function by interferon-gamma in X-linked chronic granulomatous disease occurs at the level of a progenitor cell. Blood. 1990 Dec 15; 76(12):2443-8.
  77. Oppenheim A, Yaari A, Rund D, Rachmilewitz EA, Nathan D, Wong C, Kazazian HH, Miller B. Intrinsic potential for high fetal hemoglobin production in a Druz family with beta-thalassemia is due to an unlinked genetic determinant. Hum Genet. 1990 Dec; 86(2):175-80.
  78. Bierer BE, Nathan DG. The effect of desferrithiocin, an oral iron chelator, on T-cell function. Blood. 1990 Nov 15; 76(10):2052-9.
  79. Nathan DG. The treatment of Cooley's anemia. Haematologica. 1990 Sep-Oct; 75 Suppl 5:57-65.
  80. Fosburg MT, Nathan DG. Treatment of Cooley's anemia. Blood. 1990 Aug 01; 76(3):435-44.
  81. Mathey-Prevot B, Andrews NC, Murphy HS, Kreissman SG, Nathan DG. Positive and negative elements regulate human interleukin 3 expression. Proc Natl Acad Sci U S A. 1990 Jul; 87(13):5046-50.
  82. Nathan DG. Regulation of hematopoiesis. Pediatr Res. 1990 May; 27(5):423-31.
  83. Nathan DG, Piomelli S. Oral iron chelators. Semin Hematol. 1990 Apr; 27(2):83-5.
  84. Nathan DG. The Jeremiah Metzger lecture. Regulation of hematopoiesis. Trans Am Clin Climatol Assoc. 1990; 101:135-53.
  85. Nathan DG. Pharmacologic manipulation of fetal hemoglobin in the hemoglobinopathies. Ann N Y Acad Sci. 1990; 612:179-83.
  86. Nathan DG. The beneficence of neonatal hematopoiesis. N Engl J Med. 1989 Oct 26; 321(17):1190-1.
  87. Wimperis JZ, Niemeyer CM, Sieff CA, Mathey-Prevot B, Nathan DG, Arceci RJ. Granulocyte-macrophage colony-stimulating factor and interleukin-3 mRNAs are produced by a small fraction of blood mononuclear cells. Blood. 1989 Oct; 74(5):1525-30.
  88. Wong C, Antonarakis SE, Goff SC, Orkin SH, Forget BG, Nathan DG, Giardina PJ, Kazazian HH. Beta-thalassemia due to two novel nucleotide substitutions in consensus acceptor splice sequences of the beta-globin gene. Blood. 1989 Mar; 73(4):914-8.
  89. Niemeyer CM, Sieff CA, Mathey-Prevot B, Wimperis JZ, Bierer BE, Clark SC, Nathan DG. Expression of human interleukin-3 (multi-CSF) is restricted to human lymphocytes and T-cell tumor lines. Blood. 1989 Mar; 73(4):945-51.
  90. Sieff CA, Ekern SC, Nathan DG, Anderson JW. Combinations of recombinant colony-stimulating factors are required for optimal hematopoietic differentiation in serum-deprived culture. Blood. 1989 Feb 15; 73(3):688-93.
  91. Miller BA, Salameh M, Ahmed M, Olivieri N, Huisman TH, Orkin SH, Nathan DG. Saudi Arabian sickle cell anemia. A molecular approach. Ann N Y Acad Sci. 1989; 565:143-51.
  92. Andrews NC, Mathey-Prevot B, Murphy H, Nathan DG. Regulation of the human interleukin-3 gene. Trans Assoc Am Physicians. 1989; 102:240-51.
  93. Sieff CA, Ekern S, Nathan DG. Combinations of purified recombinant colony-stimulating factors are required for optimal hematopoietic differentiation. Trans Assoc Am Physicians. 1988; 101:282-7.
  94. Emerson SG, Sieff CA, Gross RG, Rozans MK, Miller RA, Rappeport JM, Nathan DG. Decreased hematopoietic accessory cell function following bone marrow transplantation. Exp Hematol. 1987 Nov; 15(10):1013-21.
  95. Nathan DG. Leukemia and the regulation of hematopoiesis. Leukemia. 1987 Oct; 1(10):683-96.
  96. Miller BA, Salameh M, Ahmed M, Olivieri N, Antognetti G, Orkin SH, Huisman TH, Nathan DG. Analysis of hemoglobin F production in Saudi Arabian families with sickle cell anemia. Blood. 1987 Sep; 70(3):716-20.
  97. Sieff CA, Niemeyer CM, Nathan DG, Ekern SC, Bieber FR, Yang YC, Wong G, Clark SC. Stimulation of human hematopoietic colony formation by recombinant gibbon multi-colony-stimulating factor or interleukin 3. J Clin Invest. 1987 Sep; 80(3):818-23.
  98. Nienhuis AW, Donahue RE, Karlsson S, Clark SC, Agricola B, Antinoff N, Pierce JE, Turner P, Anderson WF, Nathan DG. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) shortens the period of neutropenia after autologous bone marrow transplantation in a primate model. J Clin Invest. 1987 Aug; 80(2):573-7.
  99. Miller BA, Olivieri N, Salameh M, Ahmed M, Antognetti G, Huisman TH, Nathan DG, Orkin SH. Molecular analysis of the high-hemoglobin-F phenotype in Saudi Arabian sickle cell anemia. N Engl J Med. 1987 Jan 29; 316(5):244-50.
  100. Nathan DG. Regulation of fetal hemoglobin synthesis in sickle cell anemia. Trans Am Clin Climatol Assoc. 1987; 98:21-8.
  101. Miller BA, Salameh M, Ahmed M, Olivieri N, Huisman TH, Orkin SH, Nathan DG. Analysis of high fetal hemoglobin production in sickle cell anemia patients from the Eastern Province of Saudi Arabia. Prog Clin Biol Res. 1987; 251:415-26.
  102. Alter BP, Weinberg RS, Linch DC, Schofield JM, Jackson BT, Piasecki GJ, Thornton JC, Nathan DG. Investigations of the simian ontogenic switch from fetal to adult hemoglobin at the progenitor cell level. J Clin Invest. 1986 Dec; 78(6):1497-503.
  103. Miller BA, Salameh M, Ahmed M, Wainscoat J, Antognetti G, Orkin S, Weatherall D, Nathan DG. High fetal hemoglobin production in sickle cell anemia in the eastern province of Saudi Arabia is genetically determined. Blood. 1986 May; 67(5):1404-10.
  104. Sieff CA, Emerson SG, Mufson A, Gesner TG, Nathan DG. Dependence of highly enriched human bone marrow progenitors on hemopoietic growth factors and their response to recombinant erythropoietin. J Clin Invest. 1986 Jan; 77(1):74-81.
  105. Antin JH, Ginsburg D, Smith BR, Nathan DG, Orkin SH, Rappeport JM. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment. Blood. 1985 Dec; 66(6):1247-50.
  106. Emerson SG, Sieff CA, Wang EA, Wong GG, Clark SC, Nathan DG. Purification of fetal hematopoietic progenitors and demonstration of recombinant multipotential colony-stimulating activity. J Clin Invest. 1985 Sep; 76(3):1286-90.
  107. Letvin NL, Linch DC, Beardsley GP, McIntyre KW, Miller BA, Nathan DG. Influence of cell cycle phase-specific agents on simian fetal hemoglobin synthesis. J Clin Invest. 1985 Jun; 75(6):1999-2005.
  108. Linch DC, Lipton JM, Nathan DG. Identification of three accessory cell populations in human bone marrow with erythroid burst-promoting properties. J Clin Invest. 1985 Apr; 75(4):1278-84.
  109. Friedman AD, Linch DC, Miller B, Lipton JM, Javid J, Nathan DG. Determination of the hemoglobin F program in human progenitor-derived erythroid cells. J Clin Invest. 1985 Apr; 75(4):1359-68.
  110. Nathan DG. Regulation of fetal hemoglobin synthesis by cell cycle specific drugs. Prog Clin Biol Res. 1985; 191:475-500.
  111. Wolfe L, Sallan D, Nathan DG. Current therapy and new approaches to the treatment of thalassemia major. Ann N Y Acad Sci. 1985; 445:248-55.
  112. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984 Aug; 74(2):652-6.
  113. Letvin NL, Linch DC, Beardsley GP, McIntyre KW, Nathan DG. Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med. 1984 Apr 05; 310(14):869-73.
  114. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea increases fetal hemoglobin production in sickle cell anemia. Trans Assoc Am Physicians. 1984; 97:268-74.
  115. Shahidi NT, Nathan DG, Diamond LK. Nutrition classics: the Journal of Clinical Investigation, volume 43, 1964. Iron deficiency anemia associated with an error of iron metabolism in two siblings. Nutr Rev. 1983 Oct; 41(10):315-7.
  116. Lipton JM, Nadler LM, Canellos GP, Kudisch M, Reiss CS, Nathan DG. Evidence for genetic restriction in the suppression of erythropoiesis by a unique subset of T lymphocytes in man. J Clin Invest. 1983 Aug; 72(2):694-706.
  117. Macklis RM, Javid J, Lipton JM, Kudisch M, Pettis PK, Nathan DG. Synthesis of hemoglobin F in adult simian erythroid progenitor-derived colonies. J Clin Invest. 1982 Oct; 70(4):752-61.
  118. Platt OS, Lux SE, Nathan DG. Exercise-induced hemolysis in xerocytosis. Erythrocyte dehydration and shear sensitivity. J Clin Invest. 1981 Sep; 68(3):631-8.
  119. Orkin SH, Goff SC, Nathan DG. Heterogeneity of DNA deletion in gamma delta beta-thalassemia. J Clin Invest. 1981 Mar; 67(3):878-84.
  120. Alter BP, Jackson BT, Lipton JM, Piasecki GJ, Jackson PL, Kudisch M, Nathan DG. Control of the simian fetal hemoglobin switch at the progenitor cell level. J Clin Invest. 1981 Feb; 67(2):458-66.
  121. Orkin SH, Nathan DG. The molecular genetics of thalassemia. Adv Hum Genet. 1981; 11:233-80.
  122. Weinstein HJ, Mayer RJ, Rosenthal DS, Camitta BM, Coral FS, Nathan DG, Frei E. Treatment of acute myelogenous leukemia in children and adults. N Engl J Med. 1980 Aug 28; 303(9):473-8.
  123. Lipton JM, Nathan DG. Aplastic and hypoplastic anemia. Pediatr Clin North Am. 1980 May; 27(2):217-35.
  124. Nathan DG, Alter BP. F-cell regulation. Ann N Y Acad Sci. 1980; 344:219-32.
  125. Lipton JM, Link NA, Breard J, Jackson PL, Clarke BJ, Nathan DG. Monocytes do not inhibit peripheral blood erythroid burst forming unit colony formation. J Clin Invest. 1980 Jan; 65(1):219-23.
  126. Alter BP, Orkin SH, Forget BG, Nathan DG. Prenatal diagnosis of hemoglobinopathies: the New England approach. Ann N Y Acad Sci. 1980; 344:151-64.
  127. Propper RD, Button LN, Nathan DG. New approaches to the transfusion management of thalassemia. Blood. 1980 Jan; 55(1):55-60.
  128. Nathan DG, Alter BP, Orkin SH. Prenatal diagnosis of hemoglobinopathies. Clin Perinatol. 1979 Sep; 6(2):275-91.
  129. Nathan DG. Progress in thalassemia research. Nature. 1979 Jul 26; 280(5720):275-6.
  130. Orkin SH, Old J, Lazarus H, Altay C, Gurgey A, Weatherall DJ, Nathan DG. The molecular basis of alpha-thalassemias: frequent occurrence of dysfunctional alpha loci among non-Asians with Hb H disease. Cell. 1979 May; 17(1):33-42.
  131. Orkin SH, Old JM, Weatherall DJ, Nathan DG. Partial deletion of beta-globin gene DNA in certain patients with beta 0-thalassemia. Proc Natl Acad Sci U S A. 1979 May; 76(5):2400-4.
  132. Orkin SH, Alter BP, Altay C, Mahoney MJ, Lazarus H, Hobbins JC, Nathan DG. Application of endonuclease mapping to the analysis and prenatal diagnosis of thalassemias caused by globin-gene deletion. N Engl J Med. 1978 Jul 27; 299(4):166-72.
  133. Fairweather DV, Modell B, Berdoukas V, Alter BP, Nathan DG, Loukopoulos D, Wood W, Clegg JB, Weatherall DJ. Antenatal diagnosis of thalassaemia major. Br Med J. 1978 Feb 11; 1(6109):350-3.
  134. Nathan DG, Clarke BJ, Hillman DG, Alter BP, Housman DE. Erythroid precursors in congenital hypoplastic (Diamond-Blackfan) anemia. J Clin Invest. 1978 Feb; 61(2):489-98.
  135. Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF, Rosenthal A, Nathan DG. Continuous subcutaenous administration of deferoxamine in patients with iron overload. N Engl J Med. 1977 Aug 25; 297(8):418-23.
  136. Cooper B, Bunn HF, Propper RD, Nathan DG, Rosenthal DS, Moloney WC. Evaluation of continuous desferrioxamine administration in adults with transfusional hemosiderosis. Trans Assoc Am Physicians. 1977; 90:335-41.
  137. Nathan DG. Fetal research: an investigator's view. Villanova Law Rev. 1977 Jan; 22(2):384-94.
  138. Alter BP, Nathan DG, Modell CB, Fairweather D, Mahoney MJ, Hobbins JC. Prenatal diagnosis of hemoglobinopathies: detection of alpha-thalassemia trait and of sickle cell disease in utero. Hemoglobin. 1977; 1(4):395-400.
  139. Alter BP, Modell CB, Fairweather D, Hobbins JC, Mahoney MJ, Frigoletto FD, Sherman AS, Nathan DG. Prenatal diagnosis of hemoglobinopathies. A review of 15 cases. N Engl J Med. 1976 Dec 23; 295(26):1437-43.
  140. Orkin SH, Nathan DG. The thalassemias. N Engl J Med. 1976 Sep 23; 295(13):710-4.
  141. Propper RD, Shurin SB, Nathan DG. Reassessment of the use of desferrioxamine B in iron overload. N Engl J Med. 1976 Jun 24; 294(26):1421-3.
  142. Alter BP, Friedman S, Hobbins JC, Mahoney MJ, Sherman AS, McSweeney JF, Nathan DG, Schwartz E. Prenatal diagnosis of sickle-cell anemia and alpha G Philadelphia. Study of a Fetus also at risk for H b S/beta+-thalassemia. N Engl J Med. 1976 May 06; 294(19):1040-1.
  143. Buchanan GR, Boxer LA, Nathan DG. The acute and transient nature of idiopathic immune hemolytic anemia in childhood. J Pediatr. 1976 May; 88(5):780-3.
  144. Orkin SH, Nathan DG. The molecular genetics of thalassemia. Birth Defects Orig Artic Ser. 1976; 12(8):145-59.
  145. Forget BG, Nathan DG. Molecular pathology of the thalassemias. Adv Intern Med. 1976; 21:97-128.
  146. Chang H, Modell CB, Alter BP, Dickinson MJ, Frigoletto FD, Huehns ER, Nathan DG. Expression of the beta-thalassemia gene in the first trimester fetus. Proc Natl Acad Sci U S A. 1975 Sep; 72(9):3633-7.
  147. Nathan DG, Alter BP, Frigoletto FD. Antenatal diagnosis of hemoglobinopathies: social and technical considerations. Semin Hematol. 1975 Jul; 12(3):305-21.
  148. Jensen M, Oski FA, Nathan DG, Bunn HF. Hemoglobin Syracuse (alpha2beta2-143(H21)His leads to Pro), a new high-affinity variant detected by special electrophoretic methods. Observations on the auto-oxidation of normal and variant hemoglobins. J Clin Invest. 1975 Mar; 55(3):469-77.
  149. Nathan DG. Progress in the methodology for antenatal diagnosis of the beta chain hemoglobinopathies. Trans Assoc Am Physicians. 1975; 88:168-76.
  150. Nathan DG. Ethical problems in fetal research. J Gen Educ. 1975; 27(3):165-75.
  151. Forget BG, Nathan DG. Thalassemia. Annu Rev Med. 1975; 26:345-51.
  152. Chang H, Hobbins JC, Cividalli G, Frigoletto FD, Mahoney MJ, Kan YW, Nathan DG. In utero diagnosis of: hemoglobinopathies. Hemoglobin synthesis in fetal red cells. N Engl J Med. 1974 May 09; 290(19):1067-8.
  153. Cividalli G, Nathan DG, Kan YW, Santamarina B, Frigoletto F. Relation of beta to gamma synthesis during the first trimester: an approach to prenatal diagnosis of thalassemia. Pediatr Res. 1974 May; 8(5):553-60.
  154. Kan YW, Nathan DG, Cividalii G, Frigoletto F. Intrauterine diagnosis of thalassemia. Ann N Y Acad Sci. 1974; 232(0):145-51.
  155. Jensen M, Bunn HF, Halikas G, Kan YW, Nathan DG. Effects of cyanate and 2,3-diphosphoglycerate on sickling. Relationship to oxygenation. J Clin Invest. 1973 Oct; 52(10):2542-7.
  156. Li FP, Alter BP, Nathan DG. The mortality of acquired aplastic anemia in children. Blood. 1972 Aug; 40(2):153-62.
  157. Kan YW, Nathan DG, Lodish HF. Equal synthesis of - and -globin chains in erythroid precursors in heterozygous -thalassemia. J Clin Invest. 1972 Jul; 51(7):1906-9.
  158. Feig SA, Segel GB, Shohet SB, Nathan DG. Energy metabolism in human erythrocytes. II. Effects of glucose depletion. J Clin Invest. 1972 Jun; 51(6):1547-54.
  159. Nathan DG. Thalassemia. N Engl J Med. 1972 Mar 16; 286(11):586-94.
  160. Lubin BH, Shohet SB, Nathan DG. Changes in fatty acid metabolism after erythrocyte peroxidation: stimulation of a membrane repair process. J Clin Invest. 1972 Feb; 51(2):338-44.
  161. Kan YW, Forget BG, Nathan DG. Gamma-beta thalassemia: a cause of hemolytic disease of the newborn. N Engl J Med. 1972 Jan 20; 286(3):129-34.
  162. Baehner RL, Nathan DG, Castle WB. Oxidant injury of caucasian glucose-6-phosphate dehydrogenase-deficient red blood cells by phagocytosing leukocytes during infection. J Clin Invest. 1971 Dec; 50(12):2466-73.
  163. Eckstein MR, Baehner RL, Nathan DG. Amino acid oxidase of leukocytes in relation to H 2 O 2 -mediated bacterial killing. J Clin Invest. 1971 Sep; 50(9):1985-91.
  164. Feig SA, Shohet SB, Nathan DG. Energy metabolism in human erythrocytes. I. Effects of sodium fluoride. J Clin Invest. 1971 Aug; 50(8):1731-7.
  165. Mentzer WC, Baehner RL, Schmidt-Schönbein H, Robinson SH, Nathan DG. Selective reticulocyte destruction in erythrocyte pyruvate kinase deficiency. J Clin Invest. 1971 Mar; 50(3):688-99.
  166. Maisels MJ, Pathak A, Nelson NM, Nathan DG, Smith CA. Endogenous production of carbon monoxide in normal and erythroblastotic newborn infants. J Clin Invest. 1971 Jan; 50(1):1-8.
  167. Altay C, Alper CA, Nathan DG. Normal and variant isoenzymes of human blood cell hexokinase and the isoenzyme patterns in hemolytic anemia. Blood. 1970 Aug; 36(2):219-27.
  168. Baehner RL, Nathan DG, Karnovsky ML. Correction of metabolic deficiencies in the leukocytes of patients with chronic granulomatous disease. J Clin Invest. 1970 May; 49(5):865-70.
  169. Kan YW, Nathan DG. Mild thalassemia: the result of interactions of alpha and beta thalassemia genes. J Clin Invest. 1970 Apr; 49(4):635-42.
  170. Nathan DG. Mild thalassemia--a guide to therapy. N Engl J Med. 1969 Dec 11; 281(24):1363-4.
  171. Kan YW, Schwartz E, Nathan DG. Globin chain synthesis in the alpha thalassemia syndromes. J Clin Invest. 1969 Nov; 47(11):2512-22.
  172. Nathan DG, Baehner RL, Weaver DK. Failure of nitro blue tetrazolium reduction in the phagocytic vacuoles of leukocytes in chronic granulomatous disease. J Clin Invest. 1969 Oct; 48(10):1895-904.
  173. Nathan DG, Stossel TB, Gunn RB, Zarkowsky HS, Laforet MT. Influence of hemoglobin precipitation on erythrocyte metabolism in alpha and beta thalassemia. J Clin Invest. 1969 Jan; 48(1):33-41.
  174. Shohet SB, Nathan DG, Karnovsky ML. Stages in the incorporation of fatty acids into red blood cells. J Clin Invest. 1968 May; 47(5):1096-108.
  175. Gabuzda TG, Nathan DG, Gardner FH, Kreimer-Birnbaum M, Bannerman RM. Hemoglobin F and beta thalassemia. Science. 1967 Sep 01; 157(3792):1079.
  181. NATHAN DG, GARDNER FH. Erythroid cell maturation and hemoglobin synthesis in megaloblastic anemia. J Clin Invest. 1962 May; 41:1086-93.
  182. NATHAN DG, PIOMELLI S, GARDNER FH. The synthesis of heme and globin in the maturing human erythroid cell. J Clin Invest. 1961 Jun; 40:940-6.
  183. GARDNER FH, NATHAN DG. Hypochromic anemia and hemochromatosis--response to combined testosterone, pyridoxine, and liver extract therapy. Trans Am Clin Climatol Assoc. 1961; 73:121-35.
  184. WARREN KS, NATHAN DG. The passage of ammonia across the blood-brain-barrier and its relation to blood pH. J Clin Invest. 1958 Dec; 37(12):1724-8.
To schedule an appointment: Call 617-632-2155


Boston Children’s is so much more than a hospital—it’s a community of researchers, clinicians, administrators, support staff, innovators, teachers, patients and families, all working together to make the impossible possible. ”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital
300 Longwood Avenue, Boston, MA 02115
For Patients: 617-355-6000
For Referring Providers: 844-BCH-PEDS | 844-224-7337